Improving the fate of severely infected patients: the promise of anti-toxin treatments and superiority trials.

about

Improving the fate of severely infected patients: the promise of anti-toxin treatments and superiority trials.

Item

http://www.wikidata.org/entity/Q54323383

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Improving the fate of severely ...... tments and superiority trials.

@en

Improving the fate of severely ...... tments and superiority trials.

@nl

type

Item

label

Improving the fate of severely ...... tments and superiority trials.

@en

Improving the fate of severely ...... tments and superiority trials.

@nl

prefLabel

Improving the fate of severely ...... tments and superiority trials.

@en

Improving the fate of severely ...... tments and superiority trials.

@nl

P1476

Improving the fate of severely ...... tments and superiority trials.

@en

P2093

Antonio Perez

http://www.w3.org/2001/XMLSchema#string

Samareh Azeredo da Silveira

http://www.w3.org/2001/XMLSchema#string

P2860

The role of pneumolysin in pneumococcal pneumonia and meningitis

Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net.

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

Role of pore-forming toxins in bacterial infectious diseases.

CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.

Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia

Staphylococcus aureus toxins.

Pseudomonas aeruginosa: breaking down barriers.

Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice.

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

P304

973-975

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1080/14787210.2017.1400908

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29098906

http://www.w3.org/2001/XMLSchema#string